By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Fibrinogen (human) (monograph)
Drugs

Fibrinogen (human) (monograph)

https://themeditary.com/drug/fibrinogen-human-monograph-6153.html
Medically Reviewed by Glamora Samuels, MD TheMediTary.Com | Reviewed: Aug 13, 2023  Additional Content by TheMediTary.Com

Generic name: riastap

Availability: Prescription only

Pregnancy & Lactation: Risk data available

Brand names: Riastap, Fibrinogen

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Fibrinogen (human) (monograph)?

Introduction

A lyophilized concentrate of highly purified fibrinogen (blood coagulation factor I) prepared from pooled human plasma from suitable donors.

Uses for Fibrinogen (Human)

Acute Bleeding Episodes

Used to control acute bleeding episodes in patients with congenital fibrinogen deficiency (i.e., afibrinogenemia [absence or extremely low concentrations of plasma fibrinogen], hypofibrinogenemia [reduced concentrations of plasma fibrinogen]); designated an orphan drug by FDA for use in this condition.

Not indicated in patients with dysfibrinogenemia (presence of abnormal or dysfunctional fibrinogen).

Fibrinogen (Human) Dosage and Administration

General

Monitor fibrinogen level. Target level is 100 mg/dL; maintain this level until hemostasis is obtained.

Each single-use vial contains between 900–1300 mg of fibrinogen (human). The actual fibrinogen potency for each lot is indicated on the vial label.

Administration

IV Administration

Administer by slow IV injection using a dedicated line.

Reconstitution

Reconstitute vial with 50 mL of sterile water for injection. Gently swirl until the lyophilized powder is completely dissolved. Do not shake the vial. The reconstituted solution should be colorless and clear to slightly opalescent and should be inspected visually for particulate matter; discard solution if cloudy or if particles are present.

Rate of Administration

Maximum rate is 5 mL/minute.

Dosage

Individualize dosage based on extent of bleeding, laboratory test results, and clinical condition of the patient.

Dosage is expressed in mg of fibrinogen and is based on weight. Administration of 70 mg/kg of fibrinogen (human) increased plasma concentration of fibrinogen by approximately 120 mg/dL in a pharmacokinetic study in 14 patients.

Pediatric Patients

Acute Bleeding Episodes
IV

When the baseline fibrinogen level is known, use the following formula:

Target fibrinogen level (mg/dL) - measured fibrinogen level (mg/dL) / 1.7 (mg/dL per mg/kg body weight) = mg of fibrinogen/body weight (in kg)

When the baseline fibrinogen level is not known, recommended dose is 70 mg/kg.

Adults

Acute Bleeding Episodes
IV

When the baseline fibrinogen level is known, use the following formula:

Target fibrinogen level (mg/dL) - measured fibrinogen level (mg/dL) / 1.7 (mg/dL per mg/kg body weight) = mg of fibrinogen/body weight (in kg)

When the baseline fibrinogen level is not known, recommended dose is 70 mg/kg.

Special Populations

No special population dosage recommendations at this time.

Detailed Fibrinogen dosage information

Related/similar drugs

fibrinogen

Warnings

Contraindications

  • History of serious immediate hypersensitivity reactions (e.g., anaphylaxis) to fibrinogen (human) or any ingredient in the formulation.

Warnings/Precautions

Warnings

Sensitivity Reactions

Allergic and/or hypersensitivity reactions may occur. Closely monitor for manifestations of hypersensitivity (e.g., hives, generalized urticaria, chest tightness, wheezing, hypotension, anaphylaxis). Immediately discontinue drug and administer appropriate treatment if hypersensitivity occurs.

Thrombosis

Thromboembolic events (e.g., MI, pulmonary embolism, DVT, arterial thrombosis) may occur. Weigh benefits of the drug against risk of thrombosis. Monitor for thrombosis.

Risk of Transmissible Agents in Plasma-derived Preparations

Potential vehicle for transmission of human viruses (e.g., HIV, hepatitis B virus [HBV], hepatitis C virus [HCV]) and other infectious agents.

Improved donor screening and viral eliminating/reducing procedures have reduced, but not completely eliminated risk of pathogen transmission with plasma-derived preparations. Possibility still exists for disease transmission. Report any suspected infections to the manufacturer at 866-915-6958.

Specific Populations

Pregnancy

Category C.

Lactation

Not studied in nursing women with congenital fibrinogen deficiency.

Pediatric Use

Evaluated in a limited number of children ≤16 years of age.

Geriatric Use

Experience in those ≥65 years of age insufficient to determine whether geriatric adults respond differently than younger adults.

Common Adverse Effects

Fever, headache.

How should I use Fibrinogen (human) (monograph)

General

Monitor fibrinogen level. Target level is 100 mg/dL; maintain this level until hemostasis is obtained.

Each single-use vial contains between 900–1300 mg of fibrinogen (human). The actual fibrinogen potency for each lot is indicated on the vial label.

Administration

IV Administration

Administer by slow IV injection using a dedicated line.

Reconstitution

Reconstitute vial with 50 mL of sterile water for injection. Gently swirl until the lyophilized powder is completely dissolved. Do not shake the vial. The reconstituted solution should be colorless and clear to slightly opalescent and should be inspected visually for particulate matter; discard solution if cloudy or if particles are present.

Rate of Administration

Maximum rate is 5 mL/minute.

Dosage

Individualize dosage based on extent of bleeding, laboratory test results, and clinical condition of the patient.

Dosage is expressed in mg of fibrinogen and is based on weight. Administration of 70 mg/kg of fibrinogen (human) increased plasma concentration of fibrinogen by approximately 120 mg/dL in a pharmacokinetic study in 14 patients.

Pediatric Patients

Acute Bleeding Episodes
IV

When the baseline fibrinogen level is known, use the following formula:

Target fibrinogen level (mg/dL) - measured fibrinogen level (mg/dL) / 1.7 (mg/dL per mg/kg body weight) = mg of fibrinogen/body weight (in kg)

When the baseline fibrinogen level is not known, recommended dose is 70 mg/kg.

Adults

Acute Bleeding Episodes
IV

When the baseline fibrinogen level is known, use the following formula:

Target fibrinogen level (mg/dL) - measured fibrinogen level (mg/dL) / 1.7 (mg/dL per mg/kg body weight) = mg of fibrinogen/body weight (in kg)

When the baseline fibrinogen level is not known, recommended dose is 70 mg/kg.

Special Populations

No special population dosage recommendations at this time.

Detailed Fibrinogen dosage information

Related/similar drugs

fibrinogen
Fibrinogen (human) (monograph) Dosage information (more detail)

More about Fibrinogen (human) (monograph) (Riastap)

Dosage information
Fibrinogen (human) (monograph) Side Effects
During pregnancy
Fibryga Prescribing Information
Drug images
Side effects
Drug class: Drugs

Patient resources

Fibrinogen Concentrate (Human)

Related treatment guides

Congenital Fibrinogen Deficiency
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by